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ABSTRACT
The Homeobox (HOX) genes encode important transcription factors showing 
deregulated expression in several cancers. However, their role in cervical cancer 
pathogenesis, remains largely unexplored. Herein, we studied their association with 
Human Papillomavirus type 16 (HPV16) mediated cervical cancers. Our previously 
published gene expression microarray data revealed a significant alteration of 12 
out of 39 HOX cluster members among cervical cancer cases, in comparison to the 
histopathologically normal controls. Of these, we validated seven (HOXA10, HOXA13, 
HOXB13, HOXC8, HOXC9, HOXC11 and HOXD10) by quantitative real-time PCR. We 
identified decreased HOXA10 expression as opposed to the increased expression of 
the rest. Such decrease was independent of the integration status of HPV16 genome, 
but correlated negatively with E7 expression in clinical samples, that was confirmed 
in vitro. HOXA10 and HOXB13 revealed association with Epithelial-Mesenchymal 
Transition (EMT). While HOXA10 expression correlated positively with E-Cadherin and 
negatively with Vimentin expression, HOXB13 showed the reverse trend. Chromatin 
immunoprecipitation study in vitro revealed the ability of E7 to increase HOX gene 
expression by epigenetic regulation, affecting the H3K4me3 and H3K27me3 status of 
their promoters, resulting from a loss of PRC2-LSD1 complex activity. Thus, besides 
identifying the deregulated expression of HOX cluster members in HPV16 positive 
cervical cancer and their association with EMT, our study highlighted the mechanism 
of HPV16 E7-mediated epigenetic regulation of HOX genes in such cancers, potentially 
serving as bedrock for functional studies in the future.
INTRODUCTION
Cervical cancer is the fourth leading cancer among 
women globally with HPV16 infection alone associating 
with ~50% of the cases [1-5]. HPV16 E7 is one of the driver 
molecules responsible for HPV-induced cellular transformation 
[6]. The ability of HPV16 E7 to interact with the host-
encoded proteins has been well-documented [7-8]. Such 
functional interactions, specifically with transcription factors, 
cumulatively influence the transcriptional process and global 
gene expression creating an environment conducive to HPV-
mediated cervical cancer pathogenesis. However, in a recent 
report from our laboratory [9] we proposed a mechanism 
of E7-mediated increase of gene expression globally, by 
affecting lncRNA HOTAIR expression and function. Such 
functional inactivation of HOTAIR, in turn, could impair 
Polycomb Repressive Complex 2 (PRC2) and Lysine Specific 
Demethylase 1(LSD1) recruitment resulting in concomitant 
loss of global gene silencing H3K27me3 marks and gain of 
gene activating H3K4me3 marks, respectively. However, such 
proposition needs experimental validation.
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HOX genes are a family of transcription factors that 
show deregulated expression in a variety of cancers and 
known as targets of PRC2-complex during embryonic 
development [10-11]. The class I HOX genes comprise of 
39 members distributed across four clusters localized in 
four different chromosomes - HOXA at 7p15.3, HOXB at 
17p21.3, HOXC at 12q13.3, and HOXD at 2q31[12-14]. 
Although many of the downstream targets of HOX genes 
are still not fully defined, it has been shown that HOX genes 
are integral to normal temporo-spatial limb [15] and organ 
[16] development along the anterior-posterior (A-P) axis.
Since HOX cluster members function as transcription 
factors, the common thought was that these show enhanced 
expression in cancers driving carcinogenesis by activating 
the downstream signalling cascades. However, several 
studies reported reduced expression of HOX cluster encoded 
molecules. Aberrant expression of HOX cluster genes is 
integral to a network of regulatory mechanisms involved 
in normal adult tissue homeostasis, and maintenance and 
activation of stem cell self-renewal process, crucial to 
malignant transformation [17-20]. The expression of genes 
belonging to the HOXC family, particularly HOXC4 to 
HOXC9, HOXC11, and HOXC13, shows predominant 
increase in most of the solid tumour types, except ovarian 
cancers. The two HOX genes most commonly activated 
in solid tumours are HOXA9 and HOXB13 [21]. Such 
activation of HOX cluster members are closely linked to the 
process of Epithelial-Mesenchymal Transition (EMT) [22-
24]. However, studies on expression profiling of HOX cluster 
genes in cervical cancers are mostly based on cell lines [25-
28], with only a couple of studies employing global gene 
expression profiling of cervical tissues [29-30]. However, 
none of these studies on cervical cancer cell lines or tissues, 
have taken into account the presence of HPV or expression 
of viral oncogenes. McLaughlin-Drubin et al., in 2011 [31], 
highlighted the increased expression of the PRC2-target HOX 
cluster genes in the presence of E7. This is concomitant with 
global loss of chromatin suppressive H3K27me3, despite the 
increased EZH2 expression, under the influence of E7 [31]. 
However, the impact of E7 on the gene activating H3K4me3 
and gene silencing H3K27me3 marks, specifically at the 
HOX promoters, has not been studied thus far.
Therefore, in this study, we focussed on elucidating 
the expression profile of HOX cluster member genes 
associated with cervical cancer pathogenesis, and their 
probable association with the Epithelial Mesenchymal 
Transition (EMT). We also aimed at identifying the 
association of HOX cluster expression with viral factors 
like HPV16 integration status and E7 expression among 
the cervical cancer cases. Finally, we elucidated the role 
of HPV16 E7 in epigenetically affecting the expression 
of HOX cluster genes through concomitant functional 
abrogation of PRC2-LSD1 complex in cervical cancer 
cell lines. Towards this, we estimated the H3K4me3 and 
H3K27me3 status of the promoters of the HOX genes with 
altered expression.
RESULTS
HOX cluster genes show significant expression 
deregulation among cervical cancer samples
To identify the HOX cluster members with 
deregulated expression among HPV16 positive cervical 
cancer cases in comparison to the histopathologically 
normal control samples (HPV negative and HPV16 
positive), microarray data generated on 20 HPV16 
positive cervical cancer cases, 11 HPV16 positive 
histopathologically normal samples and 11 HPV negative 
histopathologically normal samples (Accession No: 
GSE67522) was used. The histopathologically normal 
samples were grouped together for comparison, as the 
HPV negative and HPV16 positive normal samples did 
not reveal any differentially expressed genes as described 
in our previous study [9].
Out of 39 HOX cluster genes, the microarray 
analysis revealed expression levels of 31 genes. Of these, 
12 members of the HOX cluster portrayed significant 
differential expression among the cervical cancer cases, 
as compared to the histopathologically normal controls 
(Figure 1; Supplementary Table 1).
Validation of expression changes of seven 
deregulated HOX cluster members
We validated the expression profile of seven out of 
the twelve deregulated HOX cluster members, HOXA10, 
HOXA13, HOXB13, HOXC8, HOXC9, HOXC11 and 
HOXD10, using SYBR green based quantitative real-
time PCR. For such analysis, we used a sample set of 
seventy cervical cancer cases (44 samples harbouring 
episomal HPV16 and 26 samples harbouring integrated 
HPV16 genomes) and thirty histopathologically normal 
cervical samples (11 HPV16 positive and 19 HPV 
negative). Such analysis, confirmed significant altered 
expression of all seven HOX cluster members among 
the cervical cancer cases, in comparison with the HPV 
negative control samples (Supplementary Table 2). Of 
these, upregulation of HOXD10 has been previously 
reported from our laboratory [9]. HOXA10 was the 
only member showing significantly reduced expression, 
as opposed to the rest revealing significant increase 
in expression (Figure 2). However, none of these 
HOX cluster members showed differential expression 
between HPV16 positive non-malignant samples and 
HPV negative control samples, which was concordant 
with our observations using microarray analysis. The 
cervical cancer cases harbouring episomal and integrated 
HPV16 also failed to show significant differences in the 
expression levels of all the seven HOX cluster genes. 
This was indicative of the fact that the expression of 
HOX cluster genes was independent of the physical 
status of the HPV16 genome.
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Expression of HOXA10 and HOXB13 correlates 
with expression of EMT markers, E-Cadherin 
and Vimentin
Deregulated expression of several HOX genes 
in cervical cancer cases prompted us to interrogate the 
impact of such changes in cervical cancer pathogenesis. 
Existing reports [21-24], highlight the role of some 
HOX cluster members in driving metastasis, by the 
induction of Epithelial Mesenchymal Transition (EMT). 
We therefore determined the expression of EMT 
markers, E-Cadherin and Vimentin, by quantitative 
real-time PCR, among the same set of samples used 
for the validation of the expression levels of the HOX 
cluster members.
E-Cadherin expression was significantly decreased 
among the cervical cancer cases (9.85-fold; p=0.024) 
as compared to the HPV negative control samples. The 
cervical cancer samples with episomal HPV16 genome 
showed a reduction by 11.79-fold (p=0.03), while the 
cervical cancer samples with integrated HPV16 genomes 
showed a reduction by 6.02-fold (p=0.04) (Figure 3A). 
However, such difference between the two cervical cancer 
subtypes was not statistically significant. Vimentin, on the 
other hand, showed a significantly increased expression 
among the cervical cancer cases (3.83-fold; p=0.001), 
as compared to the HPV negative control samples. The 
cervical cancer samples with episomal and integrated 
HPV16 genomes showed significantly increased 
expression of Vimentin by 3.66-fold (p<0.001) and 5.44-
fold (p=0.014), respectively (Figure 3B). Both E-Cadherin 
and Vimentin expression failed to differ significantly 
between the cervical cancer cases with episomal and 
integrated HPV16 genomes.
Figure 1: Altered expression of 4 HOX clusters (covered in microarray) among cervical cancers as compared 
to histopathologically normal samples. (A – D) represent genes belonging to the clusters, HOXA, HOXB, HOXC and HOXD, 
respectively. (Blue dots: Histopathologically normal controls samples; Yellow dots: HPV16 positive cervical cancer cases; * Statistically 
significantly up-regulated among cervical cancer cases with p<0.05).
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Expression of both the EMT markers, E-Cadherin 
and Vimentin, showed correlation with the expression 
of the HOX cluster members, HOXA10 and HOXB13 
(Supplementary Tables 3 and 4). While HOXA10 
showed a positive correlation with E-Cadherin (Pearson’s 
Correlation Coefficient=0.645; p=0.0017) and a negative 
correlation with Vimentin (Pearson’s Correlation 
Coefficient=-0.456; p=0.014), the reverse trend was 
observed for HOXB13. HOXB13 showed a negative 
correlation with E-Cadherin (Pearson’s Correlation 
Figure 2: Box plots representing distribution of the expression levels of the HOX cluster genes based on real time 
PCR analysis. (A – F) corresponds to HOX cluster members such as HOXA10, HOXA13, HOXB13, HOXC8, HOXC9, HOXC11, 
respectively, among different categories of cervical samples.
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Coefficient= -0.467; p=0.0014) and a positive correlation 
with Vimentin (Pearson’s Correlation Coefficient=0.328; 
p=0.035). Thus the correlation plots of HOXA10 and 
HOXB13 with the EMT markers (Figure 3C–3F), suggest 
a role of HOXA10 and HOXB13 in driving metastasis in 
cervical cancer.
HOXA10 and HOXD10 expression correlates 
with HPV16 E7 expression
Existing reports show enhanced E-Cadherin 
expression in response to silencing of E7 in HPV16 
positive keratinocytes [32]. Thus, the correlation between 
HOXA10 and HOXB13 and the EMT markers, E-Cadherin 
and Vimentin, was indicative of an interactive role of E7 
and HOX cluster genes. In addition, HPV16 E7 impairs 
the activity of the Polycomb repressive complex, a known 
regulator of HOX cluster genes, resulting in decreased global 
H3K27me3 marks [31]. Such observations prompted us to 
determine if the expression of HOX cluster genes showed 
any correlation with HPV16 E7 expression among the case 
samples. For this, we first considered the microarray based 
data for the HOX genes showing deregulated expression 
(Supplementary Table 5). Subsequently, we validated 
the results employing qRT-PCR data on larger number of 
samples. Only, HOXA10 and HOXD10 expression showed 
a statistically significant negative correlation with HPV16 
E7 expression (Pearson’s correlation coefficients=-0.368 
and -0.472, respectively; p=0.032 and 0.001, respectively; 
Figure 4). We further confirmed the negative correlation 
between HOXA10 and HPV16 E7 expressions in vitro, 
where HOXA10 showed significantly reduced expression 
(450-fold, p<0.001) in C33A cells transfected with E7 
expressing plasmid, as compared to untransfected C33A 
cells (Supplementary Figure 1).
The increased HOXD10 expression among the 
cervical cancer cases recorded in our previous report, 
correlated negatively with lncRNA HOTAIR expression 
[9]. HOTAIR is known to trans regulate HOXD10, 
through PRC2-LSD1 complex recruitment. However, 
the reduction of HOTAIR expression among the cervical 
cancers could be responsible for the loss of such gene 
silencing and hence HOXD10 upregulation, which 
demanded further validation.
HPV16 E7 mediated alteration of HOX gene 
expression and histone methylation (H3K4me3 
and H3K27me3) status at the promoters of HOX 
cluster members
In our previous study, the increased expression 
of a large number of genes in cervical cancer cases, 
was explained through probable abrogation of lncRNA 
HOTAIR function in PRC2-LSD1 complex recruitment 
and repression of gene expression, under the influence of 
E7 [9]. Thus, we hypothesized that HPV16 E7 might have 
an important role to play in the activation of HOX cluster 
genes through abrogating PRC2-LSD1 complex activity, 
despite the fact that some of the HOX cluster members 
failed to show any significant correlation with HPV16 E7. 
We therefore aimed to identify the expression levels and 
status of gene activating (H3K4me3) and gene silencing 
(H3K27me3) chromatin marks at the promoters of four 
HOX cluster genes (HOXA13, HOXB13, HOXC11 and 
HOXD10). We selected these genes in view of their 
significantly enhanced expression among cervical cancer 
cases (Supplementary Tables 1 and 2). We observed that 
all the four members showed increased expression in 
the HPV negative cervical cancer cell line, C33A, upon 
transfection with HPV16 E7 expression plasmid (Figure 5; 
Supplementary Table 6).
The enhanced expression of the four HOX cluster 
members was concomitant with significant alterations 
in the gene activating H3K4me3 marks and gene 
silencing H3K27me3 marks, at their promoter regions 
(Supplementary Table 7). The promoter regions of all 
four HOX cluster members, showed an enrichment of 
H3K4me3 marks with a reduction in H3K27me3 marks 
in three of the members, HOXA13, HOXB13 and 
HOXD10 (Figure 6), explaining the increased expression 
of HOX cluster members. HOXC11 showed a concomitant 
enrichment of both H3K4me3 and H3K27me3 marks, but 
a higher fold-enrichment for H3K4me3 marks as compared 
to H3K27me3 marks, indicating progression towards gene 
activation. Such observations clearly establish our model 
of E7-dependent epigenetic regulation of HOX genes, 
through abrogation of PRC2-LSD1 complex activity.
DISCUSSION
The role of HOX gene deregulation in cancer 
development remains unexplored not only in cervical 
cancers but in other cancers as well. Thus, we undertook 
this study to identify the HOX cluster members with altered 
expression, specifically in HPV16 positive cervical cancers. 
We observed significantly increased expression of several 
HOX cluster members, excepting HOXA10, among the 
cervical cancer cases, in comparison to the healthy controls. 
This observation impressed upon us, the possibility 
that HOX gene expression increase could in turn bring 
about the activation of several cancer-related pathways, 
during cervical cancer development. None of the HOX 
cluster genes with altered expression levels, showed any 
association with the integration status of the viral genome 
(episomal/integrated). However, HPV16 E7 seemed to play 
an important role in the activation of HOX cluster genes 
despite the fact that some of the HOX cluster members 
failed to show any significant correlation with HPV16 E7.
The HOX cluster members that revealed altered 
expression in cervical cancer cases in our study, also 
show deregulated expression in one or more of the other 
cancer types. Similar to our observations, HOXA13 
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Figure 3: Box plots representing expression levels of the E-Cadherin and Vimentin among the different categories of 
cervical samples and their correlation with HOXA10 and HOXB13 expression, among cervical cancers. (A) Relative 
expression of E-Cadherin (E-Cadherin Ct – GAPDH Ct) (B) Relative expression of Vimentin (Vimentin Ct – GAPDH Ct) of samples (C) 
Correlation plot depicting significant positive correlation between HOXA10 and E-Cadherin expression (D) Correlation plot depicting 
significant negative correlation between HOXB13 and E-Cadherin expression (E) Correlation plot depicting significant positive correlation 
between HOXA10 and Vimentin expression (F) Correlation plot depicting significant negative correlation between HOXB13 and Vimentin 
expression.
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shows enhanced expression in oesophageal squamous 
cell carcinoma, gastric cancer and hepatocellular 
carcinoma [33-35]. However, its mode of action in 
cancer development is still unclear. HOXB13 activation, 
on the other hand, has been shown to be associated 
with metastasis through activation of MMP-9 [23, 36-
37], in a variety of solid tumours. The existence of a 
similar mechanism in cervical cancer demands further 
Figure 4: Linear regression analysis for correlation of (A) HOXA10 and (B) HOXD10, with HPV16 E7 expression among cervical 
cancers.
Figure 5: Box plots representing expression of (A) HOXA13, (B) HOXB13, (C) HOXC11, and (D) HOXD10, in C33A cells post-
transfection of pcDNA3.1-HPV16 E7 vector in comparison to the untransfected and mock (empty vector) transfected C33A cells.
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investigations. Studies on HOXC cluster members have 
also identified increased expression of HOXC8, HOXC9 
and HOXC11, as observed by us in this study. HOXC8 
correlates negatively with tumour growth [37] among 
pancreatic ductal adenocarcinomas, while showing 
increased expression in cervical cancers [38]. Activation 
of HOXC9 and HOXC11 in various cancers has been 
associated with cell proliferation and invasion [39-41]. 
A few studies have also highlighted that HOX cluster 
members drive metastasis, specifically by inducing 
Epithelial Mesenchymal Transition (EMT) [22-24]. In our 
study, the decreased HOXA10 expression and increased 
HOXB13 expression were associated with reduced 
E-Cadherin and enhanced Vimentin expression, proposing 
the need for further studies to establish HOXA10 and 
HOXB13 as biomarkers of metastasis in cervical cancer.
The increased expression of majority of the HOX 
cluster members was also in line with our hypothesis of 
HPV16 E7 driven abrogation of PRC2-LSD1 complex 
activity leading to loss of gene silencing. A significant 
correlation of HOXA10 and HOXD10 expression with 
HPV16 E7 expression highlighted the impact of E7 on 
HOX gene expression. One of the possible mechanism 
of HOXA10 reduction could be through HPV16 E7-
dependent activation of DNMT1 leading to HOXA10 
promoter methylation [22, 41]. On the other hand, in 
our earlier report, we interpreted the increased HOXD10 
expression in cervical cancer cases to be the result of 
E7-dependent inactivation of HOTAIR mediated gene 
silencing through PRC2-LSD1 complex [9].
Although E7 expression did not show significant 
correlation with the expression of majority of the HOX 
cluster members among the cervical cancer samples, E7 
overexpression in HPV negative cervical cancer cell line 
resulted in the activation of HOX cluster genes. Such 
differences in clinical and in vitro observations could be 
due to the heterogeneity of cancer tissues as opposed to the 
homogenous pool of cells in vitro. The gain of H3K4me3 
and loss of H3K27me3 marks at the promoters of HOX 
cluster genes could explain the activated expression of 
such genes, under the influence of HPV16 E7 expression. 
McLaughlin-Drubin et al., [31] had earlier shown that 
E7 expression reduces global H3K27me3 marks and 
increases the expression of PRC2-target HOX genes in 
Human Foreskin Keratinocytes. They interpreted this to 
be the result of transcriptional induction of KDM6A and 
KDM6B H3K27 specific demethylases, despite increased 
expression of EZH2 under the influence of E7 that results 
in the loss of EZH2 activity through Akt pathway mediated 
phosphorylation of EZH2 [31]. In this study, we clearly 
observed the concomitant and significant enrichment 
of H3K4me3 and reduction of H3K27me3 marks at the 
HOX cluster promoters, despite increased expression 
of the PRC2 complex member EZH2 as recorded in 
our previous study (9). Thus taken together, through 
this study we establish the mechanism of E7-mediated 
activation of HOX gene expression through functional 
abrogation of HOTAIR, ultimately suppressing the PRC2-
LSD1 complex activity, a model that we proposed in our 
previous study [9].
In conclusion, along with identifying altered 
expression of HOX cluster genes and their association 
with metastasis in HPV16 related cervical cancers, our 
study also highlighted the master regulatory role of 
Figure 6: q-PCR based analysis of enrichment of H3K4me3 and H3K27me3 marks at the promoters of HOX cluster 
genesin HPV negative and E7 expressing C33A cells. Fold-enrichment of H3K4me3 marks at (A) HOXA13, (B) HOXB13, (C) 
HOXC11, (D) HOXD10 promoters, Fold-enrichment of H3K27me3 marks at (E) HOXA13, (F) HOXB13, (G) HOXC11, (H) HOXD10 
promoters. (* p<0.05; **p<0.01; Abbreviations: Ab=Antibody).
Oncotarget36599www.impactjournals.com/oncotarget
HPV16 E7 in modulating the expression of HOX cluster 
genes. Such expression alteration predominantly involved 
enrichment of H3K4me3 and loss of H3K27me3 marks at 
the gene promoters. Thus global studies employing ChIP-
Seq for identifying the status of H3K4me3 and H3K27me3 
marks at the gene promoters, along with RNA-Seq, seem 
to be important to identify the concomitant changes in the 
transcriptome brought about by HPV16 E7. This would 
further identify and confirm the role of HPV16 E7 in the 
epigenetic regulation of host cellular transcription. Such 
studies would also help in identifying molecular targets 
for therapy of HPV-active cervical cancer, which have 
distinctly different molecular phenotypes from HPV-
inactive cervical cancer, as has been identified in a recent 
report studying TCGA cervical cancer data [42].
MATERIALS AND METHODS
Clinical samples and HPV16 Status
The healthy control cervical biopsy samples were 
derived from married women aged 36 – 70 years (median: 
52 years) without any prior history of cervical dysplasia/
malignancy, from Calcutta Medical College and Hospital, 
Kolkata, West Bengal, India and were histopathologically 
confirmed as normal. The Cervical cancer samples used 
for this study were derived from married subjects aged 
34 – 65 years (median: 52 years) attending a cancer 
referral hospital (Saroj Gupta Cancer Centre and Research 
Institute, South 24 Parganas, West Bengal, India). The 
cervical cancer biopsy samples were histopathologically 
confirmed as invasive squamous cell carcinomas (majority 
of which were diagnosed as moderately differentiated 
squamous cell carcinoma pathologically) categorised 
using the WHO classification and clinically diagnosed as 
stage III and above as per FIGO classification. Samples 
included in the different study groups did not differ 
significantly in terms of their median age.
The samples were collected with informed consent 
from the participants, approved by the ethical committee 
for human experimentation of the National Institute 
of Biomedical Genomics (NIBMG) and frozen post 
collection. We performed all experiments in accordance 
with the approved ethical guidelines and regulations. All 
such clinical samples were tested for their HPV/HPV16 
status by PCR based detection as described earlier [9]. 
Confirmation of the integration or episomal status of 
HPV16 was done employing APOT-coupled Taqman 
assay as described previously [43].
Microarray expression analysis of HOX cluster 
members
The microarray data was generated using 
Illumina HumanHT-12 v4 Expression Bead Chip array 
based platform generated by our laboratory [9] and 
submitted to the GEO repository (Accession Number: 
GSE67522, http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE67522). This data was used to identify the 
distinct differences of HOX cluster members at the gene 
expression level, between the HPV16 positive cervical 
cancer cases and the histopathologically normal control 
samples.
RNA isolation, reverse transcription and 
quantitative real-time PCR
RNA isolation, reverse transcription and quantitative 
real-time PCRs were all performed, as described 
previously [9]. The primers used for the expression 
analysis using qRT-PCR are listed in Supplementary 
Table 8.
Cell culture and transfection
HPV negative cell line C33A and HPV16 positive 
cell line SiHa were cultured in DMEM supplemented 
with 10% FBS, 50 Units/ml of penicillin and 50 µg/
ml of streptomycin at 37°C and 5% CO2. C33A cells 
were transfected with1 µg of plasmid pcDNA3.1-
HPV16 E7 vector generated in our laboratory [9], using 
Lipofectamine 2000 reagent according to manufacturer’s 
protocol. The cells were harvested and washed with 1X 
PBS, pH 7.4, trypsinized and collected by centrifugation 
at 300 xg for 10 minutes. The transfected cells were used 
for RNA and protein isolation. The expression of HPV16 
E7 was confirmed by Western blot (Supplementary Figure 
2; as shown in Ref. 9) The transfection experiments were 
carried out in three sets, each in triplicates.
Chromatin immunoprecipitation and 
quantitative real-time PCR
SiHa and C33A cells were cultured as described 
above. For the analysis of H3K4me3 and H3K27me3 
marks, we used SiHa cells and C33A cells, untransfected 
or transfected (HPV16 E7 expressing). The cells were 
cross-linked using formaldehyde at 1% final concentration 
and incubated at room temperature for 10 mins. The cross-
linking was quenched using glycine at a final concentration 
of 0.125M and incubated at room temperature for 5 mins, 
followed by washing twice with 1X PBS. The cells were 
harvested by scraping in 1X PBS (with Protease Inhibitor 
cocktail) and pelleting the cells by centrifugation at 300xg 
for 5 mins, at 4ºC. The cells were re-suspended in 1ml of 
SDS lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl 
pH 8.1 and protease inhibitors before use) and incubated 
on ice for 15 mins. The lysate was sonicated at 30% 
amplitude, 14 x 10 secs pulses, 20 secs pauses, followed 
by centrifugation at 14,000 rpm at 4ºC. The lysate was 
pre-cleared with 80µl of 50% slurry of Protein A Agarose 
beads for 60 mins at 4ºC, followed by centrifugation 
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at 4,000 rpm for 1 min at 4°C. Specific antibody (5µg) 
was added to the supernatant and precipitated overnight 
at 4°C with rotation. After overnight rotation, 60µl of 
blocked Protein A Agarose beads (1ml 50% bead slurry, 
0.5mg BSA) were added to the antibody/protein complex, 
followed by rotation for 60 mins at 4°C. The beads were 
pelleted by centrifugation at 1,000 rpm for 1 min at 4°C, 
followed by sequential washing with 1X Low Salt Immune 
Complex wash buffer (0.1% SDS, 1% TritonX-100, 2mM 
EDTA, 20mM Tris-HCl pH 8.1, 150mM NaCl), 1X 
High Salt Immune Complex wash Buffer (0.1% SDS, 
1% TritonX-100, 2mM EDTA, 20mM Tris-HCl pH 8.1, 
500mM NaCl), 1X LiCl Immune Complex wash Buffer 
(0.25M LiCl, 1% NP-40, 1% Deoxycholic acid sodium 
salt, 1mM EDTA, 10mM Tris-HCl pH 8.1) and 1X TE 
(10mM Tris pH 8.1, 1mM EDTA). The beads were eluted 
with freshly prepared elution buffer (1% SDS, 0.1M 
NaHCO3) and incubated at room temperature for 30 mins 
with agitation. The DNA was reverse cross-linked by 
adding 12µl of 5M NaCl per 100µl elute and incubated 
at 65°C overnight, followed by RNase A treatment and 
purified using PCR purification kit.
The purified DNA was then used for SYBR green 
based qPCR estimation in order to identify enrichment 
of H3K4me3 and H3K27me3 marks in the promoter 
regions of selected HOX cluster genes, which show 
altered expression in cancers. HPV16 positive SiHa 
cell line served as a positive control and HPV negative 
C33A cell line served as a negative control for HPV16 
E7 immunoprecipitation. The primers used for qPCR 
enrichment study are listed in Supplementary Table 9. The 
amplification plots and dissociation curves for the qPCR 
reactions are provided in Supplementary Figures 3 and 4, 
respectively. The primers targeting RPL-30 and EVX-1 
promoters were used as positive control for H3K4me3 and 
H3K27me3 enrichment (Supplementary Figures 5 and 6), 
respectively, while ZNF333-3’ served as a negative control 
for H3K4me3 and H3K27me3 enrichment (Supplementary 
Figure 7). The H3K4me3 and H3K27me3 enrichment 
status in HPV16 positive cell line SiHa have been 
illustrated in Supplementary Figure 8.
Statistical analysis
Kolmogorov-Smirnov test was used to check for the 
normality of the ΔCt values. Non-parametric test (Mann-
Whitney U Test) was performed to check for statistical 
significance of the changes in expression levels, as the 
ΔCt values did not follow normal distribution. Multiple 
sets of experiments using cell line model were compared 
using ANOVA for statistically significant differences in 
expression levels between the experimental categories. All 
statistical analyses were done using SPSS v16.0. The p 
values were reported after performing Bonferroni multiple 
testing corrections.
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